Testing a new method to detect EGFR gene mutations in lung cancer patients' blood

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the Plasma-SeqSensei™ Solid Cancer IVD Kit, a next-generation sequencing diagnostic test designed to detect EGFR mutations in the plasma of patients with non-small cell lung cancer (NSCLC). Participants must have previously undergone a cobas® EGFR Mutation Test v2 and provide a plasma sample for analysis. The goal is to assess the effectiveness of this new method compared to established testing protocols, with no risk to participants involved. The study aims to enhance diagnostic accuracy for lung cancer treatment planning.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Males or Females aged at least 18 years;
* Patients with advanced or metastatic non-small cell lung cancer at diagnosis or progression who have previously had the cobas® EGFR Mutation Test v2 (Roche) performed on a liquid biopsy with a valid result (positive or negative);
* Availability of 6 mL of plasma.

Exclusion Criteria:

* Plasma not available in sufficient quantities to perform both tests;
* Cobas test with invalid result.

Where it's running

• Istituto Oncologico Veneto
  Padova, Italy Recruiting

Study contacts

• Study coordinator: Stefano Indraccolo, Prof
• Email: stefano.indraccolo@iov.veneto.it
• Phone: 049 8215875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IBI363 plus chemotherapy before surgery for initially unresectable stage III non-small cell lung cancer

  This trial will try IBI363, an immunotherapy that targets PD‑1 and boosts IL‑2 signaling, together with platinum chemotherapy before surgery to see if it can shrink tumors enough for adults with initially unresectable stage III NSCLC.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT07408635

• Evaluating a new drug for lung cancer treatment

  This study is testing a new drug called SMS001 to see if it is safe and helps people with non-small cell lung cancer who are having surgery.

  Recruiting at 2 sites Phase 2 ToLymph Inc. · Rochester, Minnesota and 1 other locations · NCT06693336

• Lobular Breast Cancer with Low or No Hormone Receptors: Real-World International Cohort

  This study tests how hormone receptor–negative/low lobular breast cancer behaves in real-world patients by collecting data from multiple centers.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT07613151

• Virtual reality to reduce pain and anxiety during outpatient urology procedures

  This trial will try a virtual reality headset (REALICA®) to reduce pain and anxiety for adults having outpatient urology procedures such as circumcision, prostate biopsy, or flexible cystoscopy.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT07338292

• Preventing wound complications after limb sarcoma surgery with a single-use negative-pressure dressing

  This test will try a single-use negative-pressure wound dressing (PICO14) to see if it reduces wound complications after limb high-grade soft tissue sarcoma surgery in adults who received preoperative radiotherapy.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova, Italy/Padova · NCT06941194

• Advanced breast surgery techniques for better outcomes

  This study is testing new breast surgery techniques to see if they can improve cancer treatment results and the appearance of the breast for patients with early-stage breast cancer.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT06906237

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.